Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 160 articles:
HTML format
Text format



Single Articles


    August 2018
  1. MURALI B, Ren Q, Luo X, Faget DV, et al
    Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-18-0234.
    PubMed     Text format     Abstract available


  2. ZHANG FL, Cao JL, Xie HY, Sun R, et al
    Cancer-associated MORC2 mutant M276I regulates an hnRNPM-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-17-1394.
    PubMed     Text format     Abstract available


  3. ZHOU R, Bagga P, Nath K, Hariharan H, et al
    Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging (GluCEST MRI) detects glutaminase inhibition in a mouse model of triple-negative breast cancer.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3988.
    PubMed     Text format     Abstract available


    July 2018
  4. UBELLACKER JM, Baryawno N, Severe N, DeCristo MJ, et al
    Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer.
    Cancer Res. 2018 Jul 31. pii: 0008-5472.CAN-18-0548.
    PubMed     Text format     Abstract available


  5. CROSET M, Pantano F, Kan CWS, Bonnelye E, et al
    MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.
    Cancer Res. 2018 Jul 24. pii: 0008-5472.CAN-17-3058.
    PubMed     Text format     Abstract available


  6. XING F, Liu Y, Wu SY, Wu K, et al
    Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-1102.
    PubMed     Text format     Abstract available


  7. WU TC, Xu K, Martinek J, Young RR, et al
    IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-18-0413.
    PubMed     Text format     Abstract available


  8. XING Z, Zhang Y, Liang K, Yan L, et al
    Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer.
    Cancer Res. 2018 Jul 2. pii: 0008-5472.CAN-17-0385.
    PubMed     Text format     Abstract available


    June 2018
  9. ZHANG W, Wu M, Chong QY, Zhang M, et al
    Loss of estrogen-regulated MIR135A1 at 3p21.1 promotes tamoxifen resistance in breast cancer.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-18-0069.
    PubMed     Text format     Abstract available


  10. SUN R, Xie HY, Qian JX, Huang YN, et al
    FBXO22 possesses both pro-tumorigenic and anti-metastatic roles in breast cancer progression.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3647.
    PubMed     Text format     Abstract available


  11. IM YK, Najyb O, Gravel SP, McGuirk S, et al
    Interplay between ShcA signaling and PGC-1alpha triggers targetable metabolic vulnerabilities in breast cancer.
    Cancer Res. 2018 Jun 21. pii: 0008-5472.CAN-17-3696.
    PubMed     Text format     Abstract available



  12. Correction: TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Cancer Res. 2018;78:3403.
    PubMed     Text format    


  13. HE JP, Hou PP, Chen QT, Wang WJ, et al
    Flightless-I blocks p62-mediated recognition of LC3 to impede selective autophagy and promote breast cancer progression.
    Cancer Res. 2018 Jun 13. pii: 0008-5472.CAN-17-3835.
    PubMed     Text format     Abstract available


  14. GOOD CR, Panjarian S, Kelly AD, Madzo J, et al
    TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-2082.
    PubMed     Text format     Abstract available


  15. LU H, Tran L, Park Y, Chen I, et al
    Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Cancer Res. 2018 Jun 7. pii: 0008-5472.CAN-18-0270.
    PubMed     Text format     Abstract available


    May 2018
  16. JASTRZEBSKI K, Thijssen B, Kluin RJ, de Lint K, et al
    Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.
    Cancer Res. 2018 May 29. pii: 0008-5472.CAN-17-2698.
    PubMed     Text format     Abstract available


  17. MATSUNAGA N, Ogino T, Hara Y, Tanaka T, et al
    Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the anti-tumor effects of aldehyde dehydrogenase.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-17-4034.
    PubMed     Text format     Abstract available


    April 2018
  18. ZHENG YZ, Xue MZ, Shen HJ, Li XG, et al
    PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3514.
    PubMed     Text format     Abstract available


  19. AVANZATO D, Pupo E, Ducano N, Isella C, et al
    High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis.
    Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3018.
    PubMed     Text format     Abstract available


    March 2018
  20. WANG LH, Tseng CW, Kuo WH, Chan SH, et al
    Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
    Cancer Res. 2018 Mar 29. pii: 0008-5472.CAN-17-2906.
    PubMed     Text format     Abstract available


  21. ZHANG B, Chen MY, Sheng YJ, Zhuo XB, et al
    A large-scale, exome-wide association study of Han Chinese women identifies three novel loci predisposing to breast cancer.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-1721.
    PubMed     Text format     Abstract available


  22. REN D, Zhu X, Kong R, Zhao Z, et al
    Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    Cancer Res. 2018 Mar 22. pii: 0008-5472.CAN-17-2994.
    PubMed     Text format     Abstract available


  23. HOU J, Williams J, Botvinick E, Potma E, et al
    Visualization of breast cancer metabolism using multimodal non-linear optical microscopy of cellular lipids and redox state.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2618.
    PubMed     Text format     Abstract available


  24. LUAN H, Mohapatra B, Bielecki TA, Mushtaq I, et al
    Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-16-2140.
    PubMed     Text format     Abstract available


    February 2018
  25. HORNSVELD M, Smits LM, Meerlo M, van Amersfoort M, et al
    FOXO transcription factors both suppress and support breast cancer progression.
    Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2511.
    PubMed     Text format     Abstract available


  26. HAO J, Yan F, Zhang Y, Triplett A, et al
    Expression of adipocyte/macrophage fatty acid binding protein in tumor associated macrophages promotes breast cancer progression.
    Cancer Res. 2018 Feb 6. pii: 0008-5472.CAN-17-2465.
    PubMed     Text format     Abstract available


    January 2018
  27. WERFEL TA, Wang S, Jackson MA, Kavanaugh TE, et al
    Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-2388.
    PubMed     Text format     Abstract available


  28. JIAO X, Velasco-Velazquez MA, Wang M, Li Z, et al
    CCR5 governs DNA damage and breast cancer stem cell expansion.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0915.
    PubMed     Text format     Abstract available


  29. LUDWIK KA, McDonald OG, Brenin DR, Lannigan DA, et al
    ERalpha-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-2063.
    PubMed     Text format     Abstract available


  30. ZHANG Y, Manjunath M, Zhang S, Chasman D, et al
    Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-3486.
    PubMed     Text format     Abstract available


  31. NAGAHASHI M, Yamada A, Katsuta E, Aoyagi T, et al
    Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1423.
    PubMed     Text format     Abstract available


  32. EVANS MK, Brown MC, Geradts J, Bao X, et al
    XIAP regulation by MNK links MAPK and NFkappaB signaling to determine an aggressive breast cancer phenotype.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1667.
    PubMed     Text format     Abstract available


  33. SAHA M, Kumar S, Bukhari S, Balaji SA, et al
    AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2090.
    PubMed     Text format     Abstract available


  34. SARVI S, Patel H, Li J, Dodd GL, et al
    Kindlin-1 promotes pulmonary breast cancer metastasis.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-1518.
    PubMed     Text format     Abstract available


  35. NOUGAREDE A, Popgeorgiev N, Kassem L, Omarjee S, et al
    Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-0846.
    PubMed     Text format     Abstract available


    December 2017
  36. MAEDA T, Hiraki M, Jin C, Rajabi H, et al
    MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    Cancer Res. 2017 Dec 20. pii: 0008-5472.CAN-17-1636.
    PubMed     Text format     Abstract available


  37. EKAMBARAM P, Lee JL, Hubel NE, Hu D, et al
    The CARMA3-Bcl10-MALT1 Signalosome Drives NF-kappaB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-1089.
    PubMed     Text format     Abstract available


  38. SHARMA C, Wang HX, Li Q, Knoblich K, et al
    Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence.
    Cancer Res. 2017;77:6880-6890.
    PubMed     Text format     Abstract available


  39. PAOLETTI C, Cani AK, Larios JM, Hovelson DH, et al
    Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.
    Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-2686.
    PubMed     Text format     Abstract available


  40. TELONIS AG, Rigoutsos I
    Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1947.
    PubMed     Text format     Abstract available


  41. EL-SHENNAWY L, Dubrovskyi O, Kastrati I, Danes JM, et al
    Coactivation of estrogen receptor and IKK-beta induces a dormant metastatic phenotype in ER-positive breast cancer.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1686.
    PubMed     Text format     Abstract available


  42. WU Y, Zhang Z, Cenciarini ME, Proietti CJ, et al
    Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-1327.
    PubMed     Text format     Abstract available


    November 2017
  43. HOU P, Li L, Chen F, Chen Y, et al
    PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
    PubMed     Text format     Abstract available


  44. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Text format     Abstract available


  45. BYRD TT, Fousek K, Pignata A, Szot C, et al
    TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
    Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
    PubMed     Text format     Abstract available


  46. PAJIC M, Froio D, Daly S, Doculara L, et al
    miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-16-3105.
    PubMed     Text format     Abstract available


  47. CAMPBELL TM, Castro MA, deOliveira KG, Ponder BA, et al
    ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1153.
    PubMed     Text format     Abstract available


  48. CAREY JP, Karakas C, Bui T, Chen X, et al
    Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1494.
    PubMed     Text format     Abstract available


  49. PALMER JR, Castro-Webb N, Bertrand K, Bethea TN, et al
    Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.
    Cancer Res. 2017;77:6462-6469.
    PubMed     Text format     Abstract available


    October 2017
  50. PATIN EC, Soulard D, Fleury S, Hassane M, et al
    Type I IFN receptor signalling controls IL-7-dependent accumulation and activity of protumoral IL-17A-producing gammadeltaT cells in breast cancer.
    Cancer Res. 2017 Oct 25. pii: canres.1416.2017.
    PubMed     Text format     Abstract available


  51. TURCOTTE M, Allard D, Mittal D, Bareche Y, et al
    CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
    Cancer Res. 2017;77:5652-5663.
    PubMed     Text format     Abstract available


    September 2017
  52. ISHIHARA S, Inman DR, Li WJ, Ponik SM, et al
    Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells.
    Cancer Res. 2017 Sep 28. pii: canres.0569.2017.
    PubMed     Text format     Abstract available


  53. YANG A, Qin S, Schulte BA, Ethier SP, et al
    MYC Inhibition depletes cancer stem-like cells in triple-negative breast cancer.
    Cancer Res. 2017 Sep 26. pii: canres.3452.2016.
    PubMed     Text format     Abstract available


  54. TEO ZL, Versaci S, Dushyanthen S, Caramia F, et al
    Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple negative breast cancer.
    Cancer Res. 2017 Sep 25. pii: canres.2210.2017.
    PubMed     Text format     Abstract available


  55. CHEN L, Chubak J, Boudreau DM, Barlow WE, et al
    Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis.
    Cancer Res. 2017 Sep 21. pii: canres.0687.2017.
    PubMed     Text format     Abstract available


  56. DAVIES H, Morganella S, Purdie CA, Jang SJ, et al
    Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.
    Cancer Res. 2017;77:4755-4762.
    PubMed     Text format     Abstract available


  57. KATZENELLENBOGEN BS, Zhao Y, Laws MJ, Sanabria Guillen V, et al
    Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors.
    Cancer Res. 2017 Sep 13. pii: canres.1265.2017.
    PubMed     Text format     Abstract available


  58. DETHLEFSEN C, Hansen LS, Lillelund C, Andersen C, et al
    Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development.
    Cancer Res. 2017 Sep 8. doi: 10.1158/0008-5472.CAN-16-3125.
    PubMed     Text format     Abstract available


  59. METZGER E, Stepputtis SS, Strietz J, Preca BT, et al
    KDM4 inhibition targets breast cancer stem-like cells.
    Cancer Res. 2017 Sep 7. pii: canres.1754.2017.
    PubMed     Text format     Abstract available


    August 2017
  60. ROSS MH, Esser AK, Fox GC, Schmieder AH, et al
    Bone-induced expression of integrin beta3 enables targeted nanotherapy of breast cancer metastases.
    Cancer Res. 2017 Aug 30. pii: canres.1225.2017.
    PubMed     Text format     Abstract available


  61. LI J, Gao Z, Zhao D, Zhang L, et al
    PI-273, a substrate-competitive, specific small molecule inhibitor of PI4KIIalpha, inhibits the growth of breast cancer cells.
    Cancer Res. 2017 Aug 21. pii: canres.0484.2017.
    PubMed     Text format     Abstract available


  62. SAHNI JM, Gayle SS, Webb B, Weber-Bonk KL, et al
    Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors.
    Cancer Res. 2017 Aug 14. pii: canres.1571.2017.
    PubMed     Text format     Abstract available


  63. CHAN CHT, Munusamy P, Loke SY, Koh GL, et al
    Identification of Novel Breast Cancer Risk Loci.
    Cancer Res. 2017 Aug 3. pii: canres.0992.2017.
    PubMed     Text format     Abstract available


    July 2017
  64. REGGIANI F, Labanca V, Mancuso P, Rabascio C, et al
    Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression.
    Cancer Res. 2017 Jul 28. pii: canres.0914.2017.
    PubMed     Text format     Abstract available


  65. FINLAY-SCHULTZ J, Gillen AE, Brechbuhl HM, Ivie JJ, et al
    Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III.
    Cancer Res. 2017 Jul 20. pii: canres.3541.2016.
    PubMed     Text format     Abstract available


  66. RANGEL R, Guzman-Rojas L, Kodama T, Kodama M, et al
    Identification of new tumor suppressor genes in triple-negative breast cancer.
    Cancer Res. 2017 Jul 19. pii: canres.0785.2017.
    PubMed     Text format     Abstract available


  67. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer.
    Cancer Res. 2017 Jul 18. pii: canres.3152.2016.
    PubMed     Text format     Abstract available


  68. SOSSEY-ALAOUI K, Pluskota E, Bialkowska K, Szpak D, et al
    Kindlin-2 regulates the growth of breast cancer tumors by activating CSF-1-mediated macrophage infiltration.
    Cancer Res. 2017 Jul 7. pii: canres.2337.2016.
    PubMed     Text format     Abstract available


    June 2017
  69. YOU E, Huh YH, Kwon A, Kim SH, et al
    SPIN90 depletion and Microtubule Acetylation Mediate Stromal Fibroblast Activation in Breast Cancer Progression.
    Cancer Res. 2017 Jun 26. pii: canres.0657.2017.
    PubMed     Text format     Abstract available


  70. SALEH SM, Bertos NR, Gruosso T, Gigoux M, et al
    Identification of interacting stromal axes in triple-negative breast cancer.
    Cancer Res. 2017 Jun 26. pii: canres.3427.2016.
    PubMed     Text format     Abstract available


  71. HUMPHRIES B, Wang Z, Li Y, Jhan JR, et al
    ARHGAP18 downregulation by miR-200b suppresses metastasis of triple negative breast cancer by enhancing activation of RhoA.
    Cancer Res. 2017 Jun 15. pii: canres.3141.2016.
    PubMed     Text format     Abstract available


  72. FLOWERS M, Birkey Reffey S, Mertz SA, Hurlbert M, et al
    Obstacles, Opportunities and Priorities for Advancing Metastatic Breast Cancer Research.
    Cancer Res. 2017 Jun 10. doi: 10.1158/0008-5472.CAN-17-0232.
    PubMed     Text format     Abstract available


    May 2017
  73. VALDEZ KE, Elsarraj HS, Hong Y, Grimm SL, et al
    NEMO, a transcriptional target of estrogen and progesterone, is linked to tumor suppressor PML in breast cancer.
    Cancer Res. 2017 May 17. pii: canres.2794.2016.
    PubMed     Text format     Abstract available


  74. BARTON VN, Christenson JL, Gordon MA, Greene LI, et al
    Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer.
    Cancer Res. 2017 May 16. pii: canres.3240.2016.
    PubMed     Text format     Abstract available


  75. HOLM J, Eriksson L, Ploner A, Eriksson M, et al
    Assessment of breast cancer risk factors reveals subtype heterogeneity.
    Cancer Res. 2017 May 16. pii: canres.2574.2016.
    PubMed     Text format     Abstract available



  76. Correction: UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
    Cancer Res. 2017;77:2553.
    PubMed     Text format    


    April 2017
  77. LI B, Ni Chonghaile T, Fan Y, Madden S, et al
    THERAPEUTIC RATIONALE TO TARGET HIGHLY EXPRESSED CDK7 CONFERRING POOR OUTCOMES IN TRIPLE-NEGATIVE BREAST CANCER.
    Cancer Res. 2017 Apr 28. pii: canres.2546.2016.
    PubMed     Text format     Abstract available


  78. SAFONOV A, Jiang T, Bianchini G, Gyorffy B, et al
    Immune gene expression is associated with genomic aberrations in breast cancer.
    Cancer Res. 2017 Apr 20. pii: canres.3478.2016.
    PubMed     Text format     Abstract available


  79. LU K, Alcivar AL, Ma J, Foo TK, et al
    NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction.
    Cancer Res. 2017 Apr 17. pii: canres.2204.2016.
    PubMed     Text format     Abstract available


  80. WANG H, Schaefer T, Konantz M, Braun M, et al
    Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.
    Cancer Res. 2017;77:2148-2160.
    PubMed     Text format     Abstract available


  81. SANSONE P, Berishaj M, Rajasekhar VK, Ceccarelli C, et al
    Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.
    Cancer Res. 2017;77:1927-1941.
    PubMed     Text format     Abstract available


  82. GAGGIANESI M, Turdo A, Chinnici A, Lipari E, et al
    IL-4 primes the dynamics of breast cancer progression via DUSP4 inhibition.
    Cancer Res. 2017 Apr 11. pii: canres.3126.2016.
    PubMed     Text format     Abstract available


  83. HANKER AB, Estrada MV, Bianchini G, Moore PD, et al
    Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer.
    Cancer Res. 2017 Apr 10. pii: canres.2808.2016.
    PubMed     Text format     Abstract available


    March 2017
  84. TEMKO DP, Cheng YK, Polyak K, Michor F, et al
    Mathematical modeling links pregnancy-associated changes and breast cancer risk.
    Cancer Res. 2017 Mar 30. pii: canres.2504.2016.
    PubMed     Text format     Abstract available


  85. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Text format     Abstract available


  86. SHIMELIS H, Mesman RL, Von Nicolai C, Ehlen A, et al
    BRCA2 hypomorphic missense variants confer moderate risks of breast cancer.
    Cancer Res. 2017 Mar 10. pii: canres.2568.2016.
    PubMed     Text format     Abstract available


  87. HARRIS HR, Willett WC, Vaidya RL, Michels KB, et al
    An Adolescent and Early Adulthood Dietary Pattern Associated with Inflammation and the Incidence of Breast Cancer.
    Cancer Res. 2017;77:1179-1187.
    PubMed     Text format     Abstract available


  88. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
    Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2653.2016.
    PubMed     Text format     Abstract available


  89. CEJALVO JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, et al
    Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2717.2016.
    PubMed     Text format     Abstract available


  90. KA NL, Na TY, Na H, Lee MH, et al
    NR1D1 recruitment to sites of DNA damage inhibits repair and is associated with chemosensitivity of breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2099.2016.
    PubMed     Text format     Abstract available


  91. ANJANAPPA M, Cardoso AA, Cheng L, Mohamad S, et al
    Individualized breast cancer characterization through single cell analysis of tumor and adjacent-normal cells.
    Cancer Res. 2017 Mar 1. pii: canres.3308.2016.
    PubMed     Text format     Abstract available


    February 2017
  92. RUPRECHT B, Zaal EA, Zecha J, Wu W, et al
    Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis.
    Cancer Res. 2017 Feb 16. pii: canres.2976.2016.
    PubMed     Text format     Abstract available


  93. BAI L, Zhou B, Yang CY, Ji J, et al
    Targeted degradation of BET proteins in triple-negative breast cancer.
    Cancer Res. 2017 Feb 16. pii: canres.2622.2016.
    PubMed     Text format     Abstract available


  94. JACKSON W, Sosnoski DM, Ohanessian SE, Chandler P, et al
    The Role of Megakaryocytes in Breast Cancer Metastasis to Bone.
    Cancer Res. 2017 Feb 15. pii: canres.1084.2016.
    PubMed     Text format     Abstract available


  95. ZHOU R, Pantel AR, Li S, Lieberman BP, et al
    [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple Negative Breast Cancer in Response to Glutaminase Inhibition.
    Cancer Res. 2017 Feb 15. pii: canres.1945.2016.
    PubMed     Text format     Abstract available


    January 2017
  96. WU Y, Yu X, Yi X, Wu K, et al
    Aberrant phosphorylation of SMAD4 Thr277-mediated USP9x-SMAD4 interaction by free fatty acids promotes breast cancer metastasis.
    Cancer Res. 2017 Jan 23. pii: canres.2012.2016.
    PubMed     Text format     Abstract available


  97. SUAREZ-CABRERA C, Quintana RM, Bravo A, Casanova ML, et al
    A transposon-based analysis reveals RASA1 is involved in triple negative breast cancer.
    Cancer Res. 2017 Jan 20. pii: canres.1586.2016.
    PubMed     Text format     Abstract available


    December 2016
  98. SAMPSON JN, Falk RT, Schairer C, Moore SC, et al
    Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women.
    Cancer Res. 2016 Dec 23. pii: canres.1717.2016.
    PubMed     Text format     Abstract available


    November 2016
  99. JAEGER S, Igea A, Arroyo R, Alcalde V, et al
    Quantification of pathway crosstalk reveals novel synergistic drug combinations for breast cancer.
    Cancer Res. 2016 Nov 22. pii: canres.0097.2016.
    PubMed     Text format     Abstract available


  100. SHIBATA T, Watari K, Izumi H, Kawahara A, et al
    Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression.
    Cancer Res. 2016 Nov 22. pii: canres.1593.2016.
    PubMed     Text format     Abstract available


  101. KOCH M, de Jong JS, Glatz J, Symvoulidis P, et al
    Threshold analysis and biodistribution of fluorescently labeled bevacizumab in human breast cancer.
    Cancer Res. 2016 Nov 22. pii: canres.1773.2016.
    PubMed     Text format     Abstract available


  102. WANG L, Miyahira AK, Simons D, Lu X, et al
    IL-6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer.
    Cancer Res. 2016 Nov 22. pii: canres.1373.2016.
    PubMed     Text format     Abstract available


  103. WALI VB, Langdon CG, Held MA, Platt JT, et al
    Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer.
    Cancer Res. 2016 Nov 21. pii: canres.1901.2016.
    PubMed     Text format     Abstract available


  104. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
    Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
    PubMed     Text format     Abstract available


  105. DOWER CM, Bhat N, Wang EW, Wang HG, et al
    Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
    PubMed     Text format     Abstract available


  106. M ISMAIL TM, Bennett D, Platt-Higgins AM, Al-Medhtiy M, et al
    S100A4 elevation empowers expression of metastasis effector molecules in human breast cancer.
    Cancer Res. 2016 Nov 10. pii: canres.1802.2016.
    PubMed     Text format     Abstract available


  107. LI M, Yu X, Chen Q
    Chemopreventive effects of ROS targeting in a murine model of BRCA1-deficient breast cancer.
    Cancer Res. 2016 Nov 4. pii: canres.2350.2016.
    PubMed     Text format     Abstract available


    October 2016
  108. FORTNER RT, Schock H, Kaaks R, Lehtinen M, et al
    Human chorionic gonadotropin does not correlate with risk for maternal breast cancer: results from the Finnish maternity cohort.
    Cancer Res. 2016 Oct 26. pii: canres.1524.2016.
    PubMed     Text format     Abstract available


  109. METELLI A, Wu BX, Fugle CW, Rachidi S, et al
    Surface Expression of TGFbeta Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  110. CHIANG S, Weigelt B, Wen HC, Pareja F, et al
    IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  111. WEN SW, Sceneay J, Lima LG, Wong CS, et al
    The biodistribution and immune suppressive effects of breast cancer-derived exosomes.
    Cancer Res. 2016 Oct 19. pii: canres.0868.2016.
    PubMed     Text format     Abstract available



  112. Correction: Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.
    Cancer Res. 2016;76:6131-6132.
    PubMed     Text format    


  113. INGLE JN, Xie F, Ellis MJ, Goss PE, et al
    Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy.
    Cancer Res. 2016 Oct 10. pii: canres.1371.2016.
    PubMed     Text format     Abstract available



  114. Correction: Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Cancer Res. 2016;76:5907.
    PubMed     Text format    


  115. COOK KL, Soto-Pantoja DR, Clarke PA, Cruz MI, et al
    Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer.
    Cancer Res. 2016;76:5657-5670.
    PubMed     Text format     Abstract available


    September 2016
  116. MARUSYK A, Tabassum D, Janiszewska M, Place A, et al
    Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes.
    Cancer Res. 2016 Sep 26. pii: canres.1457.2016.
    PubMed     Text format     Abstract available


  117. ANDRIEU G, Tran AH, Strissel KJ, Denis GV, et al
    BRD4 regulates breast cancer dissemination through Jagged1/Notch1 signaling.
    Cancer Res. 2016 Sep 20. pii: canres.0559.2016.
    PubMed     Text format     Abstract available


  118. RAO SS, Bushnell GG, Azarin SM, Spicer G, et al
    Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo.
    Cancer Res. 2016;76:5209-18.
    PubMed     Text format     Abstract available


  119. MENDELSOHN J
    Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).
    Cancer Res. 2016;76:5192-4.
    PubMed     Text format    



  120. Correction: Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.
    Cancer Res. 2016;76:5186.
    PubMed     Text format    


    August 2016
  121. LIM SK, Lu SY, Kang SA, Tan HJ, et al
    Wnt signaling promotes breast cancer by blocking ITCH-mediated degradation of the YAP/TAZ transcriptional coactivator WBP2.
    Cancer Res. 2016 Aug 30. pii: canres.3537.2016.
    PubMed     Text format     Abstract available


  122. BLISS SA, Sinha G, Sandiford O, Williams L, et al
    Mesenchymal stem cell-derived exosomes stimulates cycling quiescence and early breast cancer dormancy in bone marrow.
    Cancer Res. 2016 Aug 28. pii: canres.1092.2016.
    PubMed     Text format     Abstract available


  123. AIROLDI I, Cocco C, Sorrentino C, Angelucci D, et al
    Interleukin-30 promotes breast cancer growth and progression.
    Cancer Res. 2016 Aug 22. pii: canres.0189.2016.
    PubMed     Text format     Abstract available


  124. ELIASSEN AH, Warner ET, Rosner B, Collins LC, et al
    Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 years.
    Cancer Res. 2016 Aug 16. pii: canres.0353.2016.
    PubMed     Text format     Abstract available


  125. TROMBERG BJ, Zhang Z, Leproux A, O'Sullivan TD, et al
    Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI).
    Cancer Res. 2016 Aug 15. pii: canres.0346.2016.
    PubMed     Text format     Abstract available


  126. PANG MF, Siedlik MJ, Han S, Stallings-Mann M, et al
    Tissue stiffness and hypoxia modulate the integrin-linked kinase ILK to control breast cancer stem-like cells.
    Cancer Res. 2016 Aug 8. pii: canres.0579.2016.
    PubMed     Text format     Abstract available


  127. FISKUS W, Coothankandaswamy V, Chen J, Ma H, et al
    SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress inducing agents.
    Cancer Res. 2016 Aug 8. pii: canres.0126.2016.
    PubMed     Text format     Abstract available


  128. HU DG, Selth L, Tarulli G, Meech R, et al
    Androgen and estrogen receptors in breast cancer co-regulate human UDP-glucuronosyltransferases 2B15 and 2B17.
    Cancer Res. 2016 Aug 5. pii: canres.3372.2015.
    PubMed     Text format     Abstract available


  129. JONES LW, Kwan ML, Weltzien EK, Chandarlapaty S, et al
    Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early Stage Breast Cancer: The LACE and Pathways Studies.
    Cancer Res. 2016 Aug 3. pii: canres.3307.2015.
    PubMed     Text format     Abstract available


  130. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
    RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
    Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
    PubMed     Text format     Abstract available


    July 2016
  131. SCHMITZ J, Schwab J, Schwenck J, Chen Q, et al
    Decoding intratumoral heterogeneity of breast cancer by multiparametric in vivo imaging: A translational study.
    Cancer Res. 2016 Jul 27. pii: canres.0642.2015.
    PubMed     Text format     Abstract available


  132. JIA M, Andreassen T, Jensen L, Bathen TF, et al
    Estrogen receptor alpha promotes breast cancer by reprogramming choline metabolism.
    Cancer Res. 2016 Jul 25. pii: canres.2910.2015.
    PubMed     Text format     Abstract available


  133. KIM W, Takyar FM, Swan K, Jeong J, et al
    Calcium-sensing receptor (CaSR) promotes breast cancer by stimulating intracrine actions of parathyroid hormone-related protein.
    Cancer Res. 2016 Jul 22. pii: canres.2614.2015.
    PubMed     Text format     Abstract available


  134. TENG Y, Qin H, Bahssan A, Bendzunas G, et al
    The WASF3-NCKAP1-CYFIP1 complex is essential for breast cancer metastasis.
    Cancer Res. 2016 Jul 18. pii: canres.0562.2016.
    PubMed     Text format     Abstract available


  135. D'IPPOLITO E, Plantamura I, Bongiovanni L, Casalini P, et al
    MiR-9 and miR-200 regulate PDGFRbeta-mediated endothelial differentiation of tumor cells in triple negative breast cancer.
    Cancer Res. 2016 Jul 11. pii: canres.0140.2016.
    PubMed     Text format     Abstract available


    June 2016
  136. XING F, Liu Y, Sharma S, Wu K, et al
    Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer.
    Cancer Res. 2016 Jun 30. pii: canres.3541.2015.
    PubMed     Text format     Abstract available


  137. CHENG CT, Kuo CY, Ouyang C, Li CF, et al
    Metabolic stress-induced phosphorylation of KAP1 Ser473 blocks mitochondrial fusion in breast cancer cells.
    Cancer Res. 2016 Jun 30. pii: canres.2921.2015.
    PubMed     Text format     Abstract available


  138. ORSO F, Quirico L, Virga F, Penna E, et al
    miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.1322.2015.
    PubMed     Text format     Abstract available


  139. LEE H, Goodarzi H, Tavazoie Corresponding Author SF, Alarcon CR, et al
    TMEM2 is a SOX4 regulated gene that mediates metastatic migration and invasion in breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.2322.2015.
    PubMed     Text format     Abstract available


  140. PHAM E, Yin M, Peters CG, Lee CR, et al
    Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer.
    Cancer Res. 2016 Jun 20. pii: canres.3435.2015.
    PubMed     Text format     Abstract available


  141. SADIK H, Korangath P, Nguyen N, Gyorffy B, et al
    HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells.
    Cancer Res. 2016 Jun 14. pii: canres.0774.2016.
    PubMed     Text format     Abstract available


  142. DOU Q, Chen HN, Wang K, Yuan K, et al
    Ivermectin induces cytostatic autophagy by blocking PAK1/Akt axis in breast cancer.
    Cancer Res. 2016 Jun 14. pii: canres.2887.2015.
    PubMed     Text format     Abstract available


  143. ITO K, Park SH, Nayak A, Byerly JH, et al
    PTK6 inhibition suppresses metastases of triple negative breast cancer via Snail-dependent E-cadherin regulation.
    Cancer Res. 2016 Jun 14. pii: canres.3445.2015.
    PubMed     Text format     Abstract available


  144. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    PHGDH Expression is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance and Lung Metastasis.
    Cancer Res. 2016 Jun 8. pii: canres.0530.2016.
    PubMed     Text format     Abstract available


    May 2016
  145. SHAVER TM, Lehmann BD, Beeler JS, Li CI, et al
    Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.
    Cancer Res. 2016 May 26. pii: canres.0058.2016.
    PubMed     Text format     Abstract available


  146. MANSOUR M, Haupt S, Chan AL, Godde N, et al
    E3 ligase E6AP represses breast cancer metastasis via regulation of ECT2-Rho signalling.
    Cancer Res. 2016 May 26. pii: canres.1553.2015.
    PubMed     Text format     Abstract available


  147. CHANG TY, Chen HA, Chiu CF, Chang YW, et al
    Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL.
    Cancer Res. 2016 May 23. pii: canres.2555.2015.
    PubMed     Text format     Abstract available


  148. SINGH M, Mukundan S, Jaramillo M, Oesterreich S, et al
    Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression.
    Cancer Res. 2016 May 23. pii: canres.2304.2015.
    PubMed     Text format     Abstract available


  149. VACCHELLI E, Enot DP, Pietrocola F, Zitvogel L, et al
    Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  150. MARSH T, Wong I, Sceneay J, Barakat A, et al
    Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression.
    Cancer Res. 2016;76:2932-2943.
    PubMed     Text format     Abstract available


  151. LATORRE E, Carelli S, Raimondi I, D'Agostino V, et al
    The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial-Mesenchymal Transition in Breast Cancer.
    Cancer Res. 2016;76:2626-2636.
    PubMed     Text format     Abstract available


    April 2016
  152. BHAT-NAKSHATRI P, Goswami CP, Badve S, Magnani L, et al
    Molecular Insights of Pathways Resulting From Two Common PIK3CA Mutations in Breast Cancer.
    Cancer Res. 2016 Apr 25. pii: canres.3174.2015.
    PubMed     Text format     Abstract available


  153. KNUTSON KL, Clynes R, Shreeder B, Yeramian P, et al
    Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain.
    Cancer Res. 2016 Apr 20. pii: canres.3091.2015.
    PubMed     Text format     Abstract available


  154. YEO SK, Wen J, Chen S, Guan JL, et al
    Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfss/Smad signaling.
    Cancer Res. 2016 Apr 13. pii: canres.2946.2015.
    PubMed     Text format     Abstract available


  155. CICHON MA, Moruzzi ME, Shqau TA, Miller E, et al
    MYC is a crucial mediator of TGFbeta-induced invasion in basal breast cancer.
    Cancer Res. 2016 Apr 13. pii: canres.3465.2015.
    PubMed     Text format     Abstract available


  156. ALHOSSINY M, Luo L, Frazier WR, Steiner N, et al
    Ly6E/K Signaling to TGFbeta Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  157. PENG D, Tanikawa T, Li W, Zhao L, et al
    Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL-6/STAT3 and NO/NOTCH cross-talk signaling.
    Cancer Res. 2016 Apr 6. pii: canres.2528.2015.
    PubMed     Text format     Abstract available


  158. LI Y, Jin K, van Pelt GW, van Dam H, et al
    c-Myb enhances breast cancer invasion and metastasis through the Wnt/beta-catenin/Axin2 pathway.
    Cancer Res. 2016 Apr 5. pii: canres.2302.2015.
    PubMed     Text format     Abstract available


    March 2016
  159. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


    January 2016
  160. COX TR, Gartland A, Erler JT
    Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.
    Cancer Res. 2016;76:188-92.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: